Chargement en cours...
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...
Enregistré dans:
| Publié dans: | Nat Commun |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5159881/ https://ncbi.nlm.nih.gov/pubmed/27959342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13122 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|